US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iPath Select MLP ETN

31.50

+0.10000.32%

Post-market: 31.520.0200+0.06%16:10 EST

Volume:61.23K

Turnover:1.93M

Market Cap:559.36M

PE:- -

High:31.65

Open:31.43

Low:31.39

Close:31.40

52wk High:31.65

52wk Low:25.66

Shares:17.76M

Float Shares:17.76M

Volume Ratio:1.69

T/O Rate:0.34%

Dividend:1.48

Dividend Rate:4.70%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Pacira BioSciences Reports Second Quarter 2025 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATMP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATMP\",,,,,undefined,":{"symbol":"ATMP","market":"US","secType":"STK","nameCN":"iPath Select MLP ETN","latestPrice":31.5,"timestamp":1770411600000,"preClose":31.4,"halted":0,"volume":61227,"hourTrading":{"tag":"盘后","latestPrice":31.52,"preClose":31.5,"latestTime":"16:10 EST","volume":107,"amount":3372.5,"timestamp":1770412204101,"change":0.02,"changeRate":0.000635,"amplitude":0},"delay":0,"changeRate":0.0031847133757962236,"floatShares":17757506,"shares":17757506,"eps":0,"marketStatus":"Market Closed","change":0.1,"latestTime":"02-06 16:00:00 EST","open":31.43,"high":31.65,"low":31.39,"amount":1929133.9934,"amplitude":0.00828,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":31.4,"sharesOutstanding":17757506,"nav":28.6244,"aum":561248383.84,"dividendRate":0.046956,"bidAskSpread":0.000965,"postHourTrading":{"tag":"盘后","latestPrice":31.52,"preClose":31.5,"latestTime":"16:10 EST","volume":107,"amount":3372.5,"timestamp":1770412204101,"change":0.02,"changeRate":0.000635,"amplitude":0},"volumeRatio":1.685144,"impliedVol":0.0585,"impliedVolPercentile":0.502},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATMP\",,,,,undefined,":{"symbol":"ATMP","floatShares":17757506,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.685144,"shares":17757506,"dividePrice":1.4791,"high":31.65,"amplitude":0.00828,"preClose":31.4,"low":31.39,"week52Low":25.66,"pbRate":"--","week52High":31.65,"institutionHeld":0,"latestPrice":31.5,"eps":0,"divideRate":0.046956,"volume":61227,"delay":0,"ttmEps":0,"open":31.43,"prevYearClose":28.77,"prevWeekClose":30.9,"prevMonthClose":30.9,"prevQuarterClose":28.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATMP\",params:#limit:5,,,undefined,":[{"date":"2025-12-01","symbol":"ATMP","amount":0.39806809,"announcedDate":"2025-11-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-01","defaultRemindTime":1764599400000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-09","payableDate":"2025-12-01","currency":"USD","dateTimestamp":1764565200000,"payDate":"2025-12-09"},{"date":"2025-08-28","symbol":"ATMP","amount":0.381190999,"announcedDate":"2025-08-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-28","defaultRemindTime":1756387800000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-08","payableDate":"2025-08-28","currency":"USD","dateTimestamp":1756353600000,"payDate":"2025-09-08"},{"date":"2025-05-29","symbol":"ATMP","amount":0.380144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-29","defaultRemindTime":1748525400000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-06","payableDate":"2025-05-29","currency":"USD","dateTimestamp":1748491200000,"payDate":"2025-06-06"},{"date":"2025-03-03","symbol":"ATMP","amount":0.31838,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"Barclays ETN+ Select MLP ETNs","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-11"},{"date":"2024-11-29","symbol":"ATMP","amount":0.35114,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-29","defaultRemindTime":1732890600000,"name":"Barclays ETN+ Select MLP ETNs","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-09","payableDate":"2024-11-29","currency":"USD","dateTimestamp":1732856400000,"payDate":"2024-12-09"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATMP\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-27","recordDate":null,"paymentDate":null,"value":0.2845092,"currency":"USD"},{"executeDate":"2017-05-24","recordDate":null,"paymentDate":null,"value":0.2714382,"currency":"USD"},{"executeDate":"2017-08-24","recordDate":null,"paymentDate":null,"value":0.302208,"currency":"USD"},{"executeDate":"2017-11-28","recordDate":null,"paymentDate":null,"value":0.2959505,"currency":"USD"},{"executeDate":"2018-02-28","recordDate":null,"paymentDate":null,"value":0.2574755,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATMP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1579,"buy":0.6316,"hold":0.1579,"sell":0.0526,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6316,"analysts":19,"updateTime":1768626000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATMP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602731367","title":"Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2602731367","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602731367?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:01","pubTimestamp":1767906060,"startTime":"0","endTime":"0","summary":"-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan.  08, 2026  (GLOBE NEWSWIRE) -- Pacira BioScience","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215775/0/en/Pacira-Reports-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2025-Revenues.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATMP"],"gpt_icon":0},{"id":"2586743219","title":"IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2586743219","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586743219?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:44","pubTimestamp":1764222240,"startTime":"0","endTime":"0","summary":"SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ --IASO Biotechnology , a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, today announced that the Biologics License Application  for its independently developed fully human anti-BCMA CAR-T therapy Fucaso  has been approved by the Hong Kong Department of Health. The therapy is indicated for adult patients with relapsed or refractory multiple myeloma  who have received three or more prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent.This approval marks the first authorization of a China-developedCAR-T cell therapy in Hong Kong  and the first China-developedATMP  to obtain PIC/S GMP recognition following Hong Kong DoH inspection. PIC/S  consists of more than 56 regulatory authorities, including the U.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/iaso-bio-announces-bla-approval-of-fucaso-equecabtagene-autoleucel-by-the-hong-kong-department-of-health-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-302627347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATMP","BLA.AU"],"gpt_icon":0},{"id":"2570091604","title":"Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2570091604","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570091604?lang=en_us&edition=fundamental","pubTime":"2025-09-25 19:15","pubTimestamp":1758798900,"startTime":"0","endTime":"0","summary":"FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response un","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/25/3156168/0/en/Capricor-Therapeutics-Provides-Regulatory-Update-on-Deramiocel-Program-for-Duchenne-Muscular-Dystrophy-Following-Type-A-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4530","BK4081","ATMP","BK4121","EMA","LU0757428866.USD","CRL","CAPR","BK4588","LU1815336091.USD","LU0390134368.USD","BK4585","BK4139"],"gpt_icon":0},{"id":"2566561849","title":"Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel","url":"https://stock-news.laohu8.com/highlight/detail?id=2566561849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566561849?lang=en_us&edition=fundamental","pubTime":"2025-09-09 21:20","pubTimestamp":1757424000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2025  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today iss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/09/3147015/0/en/Capricor-Therapeutics-Responds-to-FDA-Posting-of-Complete-Response-Letter-CRL-for-Deramiocel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","ATMP","LU0390134368.USD","LU0757428866.USD","LU1815336091.USD","BK4588","BK4530","BK4139","CRL","BK4081","BK4585","BK4121","EMA"],"gpt_icon":0},{"id":"2557031131","title":"Pacira BioSciences Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2557031131","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557031131?lang=en_us&edition=fundamental","pubTime":"2025-08-06 04:00","pubTimestamp":1754424000,"startTime":"0","endTime":"0","summary":"-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/05/3127784/0/en/Pacira-BioSciences-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATMP"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}